Component
Human sulfasalazine plasma exposure
Human sulfasalazine plasma exposure. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Sulfasalazine AUC increased 2.0-fold at the microdose and 3.2-fold at the therapeutic dose.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/curcumin-research/22300367.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe", "start_char": 0, "end_char": 1713, "text_sha256": "a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe"}
- experimental_model
- Human pharmacokinetics, transporter vesicles and mouse knockout experiment
- exposure
- Human: curcumin 2 g before sulfasalazine 100 micrograms or 2 g; eight participants. Mouse: 300-400 mg/kg curcumin
- limitations
- Small dose- and formulation-specific drug study. Transporter inference is supported by separate assays, not a universal effect on every BCRP substrate.
- nutrient_topic
- Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
- organism
- Human transporter/human participants; mouse claims separately scoped
- plain_language
- The human experiment measured more sulfasalazine in blood.
- primary_references
- [curcumin-p22300367] Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. (2012). https://pubmed.ncbi.nlm.nih.gov/22300367/ DOI: 10.1111/j.1476-5381.2012.01887.x
- tissue_or_cell_type
- Intestinal drug transport and plasma
Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 801–812
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human pharmacokinetics, transporter vesicles and mouse knockout experiment · source_derived_draft · unverified_draft
### curcumin-sulfasalazine-exposure Sulfasalazine AUC increased 2.0-fold at the microdose and 3.2-fold at the therapeutic dose. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The human experiment measured more sulfasalazine in blood. organism: Human transporter/human participants; mouse claims separately scoped tissue_or_cell_type: Intestinal drug transport and plasma experimental_model: Human pharmacokinetics, transporter vesicles and mouse knockout experiment limitations: Small dose- and formulation-specific drug study. Transporter inference is supported by separate assays, not a universal effect on every BCRP substrate. exposure: Human: curcumin 2 g before sulfasalazine 100 micrograms or 2 g; eight participants. Mouse: 300-400 mg/kg curcumin evidence_span: {"source_cache": "artifacts/curcumin-research/22300367.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe", "start_char": 0, "end_char": 1713, "text_sha256": "a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe"} [curcumin-p22300367] Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. (2012). https://pubmed.ncbi.nlm.nih.gov/22300367/ DOI: 10.1111/j.1476-5381.2012.01887.x
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.